Alanine aminotransferase-old biomarker and new concept: A review

International Journal of Medical Sciences

Volumn 11, Issue 9, 2014, Pages 925-935

  Liu, Zhengtao ^a   Que, Shuping ^b   Xu, Jing ^a   Peng, Tao ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b Women and Children Health Care Hospital of Guangxi Zhuang Autonomous Region   (China)

Author keywords

Activity; ALT; Serum alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; AUTOIMMUNE HEPATITIS; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CLINICAL PRACTICE; COFFEE; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SYNTHESIS; ETHNIC DIFFERENCE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; MEDICAL EXAMINATION; METABOLIC SYNDROME X; MUSCLE INJURY; NONALCOHOLIC FATTY LIVER; OBESITY; PRACTICE GUIDELINE; REFERENCE VALUE; REVIEW; SEX DIFFERENCE; TRANSAMINATION; UPPER LIMIT OF NORMAL; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; LIVER DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HEPATITIS B; HEPATITIS C; HUMANS; LIVER DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 84903908602     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8951     Document Type: Review

References (141)

1. Kim W, Flamm SL, Di Bisceglie AM, Bodenheimer HC: Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47(4): 1363-1370.
2. Schwartz MK: [261c] Clinical aspects of aspartate and alanine aminotransferases. Methods in enzymology 1971; 17: 866-875.
3. Giannini EG, Testa R, Savarino V: Liver enzyme alteration: a guide for clinicians. Canadian medical association journal 2005; 172(3): 367-379.
4. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. The American journal of gastroenterology 2003; 98(5): 960-967.
5. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. The Lancet 2005; 365(9468): 1415-1428.
6. Yun JE, Kim SY, Kang H-C, Lee SJ, Kimm H, Jee SH: Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance. Circulation journal: official journal of the Japanese Circulation Society 2010; 75(4): 964-969.
7. Liu Z, Hu Y, Yang X, Tan A, Gao Y, Qin X, Liang Y, Mo Z, Peng T: Combinative analysis of factors influence serum alanine aminotransferase activity in adult male population from southern China. Clinical biochemistry 2012; 45(18): 1683-1688.
8. James PT: Obesity: the worldwide epidemic. Clinics in dermatology 2004; 22(4): 276-280.
9. Pratt DS, Kaplan MM: Evaluation of abnormal liver-enzyme results in asymptomatic patients. New England Journal of Medicine 2000; 342(17): 1266-1271.
10. Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, Alavian SM: Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PloS one 2011; 6(6e): 21178.
11. Dong MH, Bettencourt R, Barrett-Connor E, Loomba R: Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PloS one 2010; 5(12e): 14254.
12. Elinav E, Ben-Dov IZ, Ackerman E, Kiderman A, Glikberg F, Shapira Y, Ackerman Z: Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. The American journal of gastroenterology 2005; 100(10): 2201-2204.
13. Dong MH, Bettencourt R, Brenner DA, Barrett-Connor E, Loomba R: Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clinical Gastroenterology and Hepatology 2012; 10(3): 285-290.
14. Córdoba J, O'Riordan K, Dupuis J, Borensztajn J, Blei AT: Diurnal variation of serum alanine transaminase activity in chronic liver disease. Hepatology 1998; 28(6): 1724-1725.
15. Pacifico L, Ferraro F, Bonci E, Anania C, Romaggioli S, Chiesa C: Upper limit of normal for alanine aminotransferase: < i> Quo vadis? Clinica Chimica Acta 2013; 422: 29-39.
16. Ruhl CE, Everhart JE: Diurnal Variation in Serum Alanine Aminotransferase Activity in the United States Population. Journal of Clinical Gastroenterology 2013; 47(2): 165.
17. Sherman KE: Alanine aminotransferase in clinical practice: a review. Archives of internal medicine 1991; 151(2): 260.
18. Ishiguro M, Takio K, Suzuki M, Oyama R, Matsuzawa T, Titani K: Complete amino acid sequence of human liver cytosolic alanine aminotransferase (GPT) determined by a combination of conventional and mass spectral methods. Biochemistry 1991; 30(43): 10451-10457.
19. Sohocki MM, Sullivan LS, Harrison WR, Sodergren EJ, Elder FF, Weinstock G, Tanase S, Daiger SP: Human glutamate pyruvate transaminase (GPT): localization to 8q24. 3, cDNA and genomic sequences, and polymorphic sites. Genomics 1997; 40(2): 247-252.
20. Toney MD: Reaction specificity in pyridoxal phosphate enzymes. Archives of biochemistry and biophysics 2005; 433(1): 279-287.
21. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even A, Horn-Saban S, Safran M, Domany E: Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics 2005; 21(5): 650-659.
22. Yang RZ, Park S, Reagan WJ, Goldstein R, Zhong S, Lawton M, Rajamohan F, Qian K, Liu L, Gong DW: Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology 2009; 49(2): 598-607.
23. Flora KD, Keeffe EB: Evaluation of mildly abnormal liver tests in asymptomatic patients. J Insur Med 1990; 22(4): 264-267.
24. Weibrecht K, Dayno M, Darling C, Bird SB: Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury. Journal of Medical Toxicology 2010; 6(3): 294-300.
25. Saengsirisuwan V, Phadungkij S, Pholpramool C: Renal and liver functions and muscle injuries during training and after competition in Thai boxers. British journal of sports medicine 1998; 32(4): 304-308.
26. Fallon K, Sivyer G, Sivyer K, Dare A: The biochemistry of runners in a 1600 km ultramarathon. British journal of sports medicine 1999; 33(4): 264-269.
27. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N: Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005; 41(2): 380-382.
28. Noakes T, Carter J: Biochemical parameters in athletes before and after having run 160 kilometres. South African medical journal= Suid-Afrikaanse tydskrif vir geneeskunde 1976; 50(40): 1562.
29. Edge K, Chinoy H, Cooper R: Serum alanine aminotransferase elevations correlate with serum creatine phosphokinase levels in myositis. Rheumatology 2006; 45(4): 487-488.
30. Hickman I, Jonsson J, Prins J, Ash S, Purdie D, Clouston A, Powell E: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53(3): 413-419.
31. BABA CS, ALEXANDER G, KALYANI B, PANDEY R, RASTOGI S, PANDEY A, CHOUDHURI G: Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. Journal of gastroenterology and hepatology 2006; 21(1): 191-198.
32. Dufour D: Effects of habitual exercise on routine laboratory tests. In: CLINICAL CHEMISTRY: 1998: AMER ASSOC CLINICAL CHEMISTRY 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA; 1998(A);: 136-136.
33. Mijovic V, Contreras M, Barbara J: Serum alanine aminotransferase (ALT) and gamma-glutamyltransferase (gamma-GT) activities in north London blood donors. Journal of clinical pathology 1987; 40(11): 1340-1344.
34. Cotler S, Dhamija M, Luc B, Siqueira F, Bartram A, Layden T, Wong S: The prevalence and clinical correlates of elevated ALT levels in an urban Chinatown community. Journal of Viral Hepatitis 2010; 17(2): 148-152.
35. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F: Prevalence and etiology of altered liver tests: A population-based survey in a Mediterranean town. Hepatology 2005; 41(5): 1151-1159.
36. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK: Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. Journal of gastroenterology and hepatology 2007; 22(9): 1482-1489.
37. Pan J-J, Qu H-Q, Rentfro A, McCormick JB, Fisher-Hoch SP, Fallon MB: Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. PloS one 2011; 6(6e): 21515.
38. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. JAMA: the journal of the American Medical Association 2002; 287(3): 356-359.
39. Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, Ito J-i, Watanabe H, Saito K, Takeda H: Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. Metabolism 2009; 58(8): 1067-1075.
40. Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387-1395.
41. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews Immunology 2005; 5(3): 215-229.
42. Liaw Y-F, Chu C-M: Hepatitis B virus infection. The Lancet 2009; 373(9663): 582-592.
43. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45(2): 507-539.
44. Dienstag JL: Hepatitis B virus infection. New England Journal of Medicine 2008; 359(14): 1486-1500.
45. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH: The clinical significance of persistently normal ALT in chronic hepatitis B infection. Journal of hepatology 2007; 47(6): 760-767.
46. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, Lau D, Hoofnagle JH: Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26(S3): 29S-33S.
47. Ruhl CE, Everhart JE: Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55(2): 447-454.
48. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. New England Journal of Medicine 1996; 334(26): 1691-1696.
49. Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, Urabe A: Risk factors for serum alanine aminotransferase elevation: A cross-sectional study of healthy adult males in Tokyo, Japan. Digestive and Liver Disease 2010; 42(12): 882-887.
50. Belfrage P, Berg B, Cronholm T, Elmqvist D, Hägerstrand I, Johansson B, Nilsson-Ehle P, Norden G, Sjövall J, Wiebe T: Prolonged administration of ethanol to young, healthy volunteers: effects on biochemical, morphological and neurophysiological parameters. Acta medica Scandinavica Supplementum 1973; 552: 1.
51. Wickramasinghe S, Corridan B, Izaguirre J, Hasan R, Marjot D: Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. Alcohol and alcoholism 1995; 30(5): 675-680.
52. Stewart SH: Racial and Ethnic Differences in Alcohol-Associated Aspartate Aminotransferase and-gamma}-Glutamyltransferase Elevation. Archives of internal medicine 2002; 162(19): 2236.
53. Alatalo PI, Koivisto HM, Hietala JP, Puukka KS, Bloigu R, Niemelä OJ: Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index. The American journal of clinical nutrition 2008; 88(4): 1097-1103.
54. Ruhl CE, Everhart JE: Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clinical Gastroenterology and Hepatology 2005; 3(12): 1260-1268.
55. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR: Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women. JAMA: the journal of the American Medical Association 2002; 287(19): 2559-2562.
56. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC: Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA: the journal of the American Medical Association 2006; 296(1): 87-93.
57. Ford I, Mooijaart SP, Lloyd S, Murray HM, Westendorp RG, de Craen AJ, Packard CJ, Buckley B, Barlow C, Preiss D: The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International journal of epidemiology 2011; 40(6): 1530-1538.
58. Tolman KG: The liver and lovastatin. The American journal of cardiology 2002; 89(12): 1374-1380.
59. Sniderman AD: Is there value in liver function test and creatine phosphokinase monitoring with statin use? The American journal of cardiology 2004; 94(9): 30-34.
60. Cohen DE, Anania FA, Chalasani N: An assessment of statin safety by hepatologists. The American journal of cardiology 2006; 97(8): S77-S81.
61. Ruhl CE, Everhart JE: Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128(1): 24-32.
62. Lee K-G, Mitchell A, Shibamoto T: Antioxidative activities of aroma extracts isolated from natural plants. Biofactors 2000; 13(1): 173-178.
63. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(6): 1413-1419.
64. Angulo P: Nonalcoholic fatty liver disease. New England Journal of Medicine 2002; 346(16): 1221-1231.
65. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes 2001; 50(8): 1844-1850.
66. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4): 917-923.
67. Liu C-M, Tung T-H, Liu J-H, Chen V, Lin C-H, Hsu C-T, Chou P: A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World J Gastroenterol 2005; 11(11): 1616-1622.
68. Liangpunsakul S, Chalasani N: Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). The American journal of the medical sciences 2005; 329(3): 111-116.
69. Sass DA, Chang P, Chopra KB: Nonalcoholic fatty liver disease: a clinical review. Digestive diseases and sciences 2005; 50(1): 171-180.
70. Charlton M: Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clinical Gastroenterology and Hepatology 2004; 2(12): 1048-1058.
71. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37(5): 1202-1219.
72. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell W: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11(1): 74-80.
73. Sonsuz A, Basaranoglu M, Ozbay G: Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. The American journal of gastroenterology 2000; 95(5): 1370-1371.
74. Muri Boberg K: Prevalence and epidemiology of autoimmune hepatitis. Clinics in liver disease 2002; 6(3): 635-647.
75. Krawitt EL: Autoimmune hepatitis. New England Journal of Medicine 2006; 354(1): 54-66.
76. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM: Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51(6): 2193-2213.
77. Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, Sakai N, Makino Y, Kobashi H, Takaguchi K: Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. Journal of hepatology 2005; 43(6): 951-957.
78. Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y: Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Alimentary pharmacology & therapeutics 2006; 24(8): 1197-1205.
79. Fabbri A, Lenzi M: Non-invasive markers of inflammation in autoimmune hepatitis. Liver International 2013; 33(9): 1295-1297.
80. Jeong S, Nam H, Rhee J, Shin J, Kim J, Cho K: Metabolic syndrome and ALT: a community study in adult Koreans. International journal of obesity 2004; 28(8): 1033-1038.
81. Suh S-Y, Choi S-E, Ahn H-Y, Yang H-M, Kim Y-I, Sung N-J: The association between normal alanine aminotransferase levels and the metabolic syndrome: 2005 Korean National Health and Nutrition Examination Survey. Metabolism 2009; 58(12): 1731-1736.
82. Lorenzo C, Hanley A, Rewers M, Haffner S: The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study. Diabetologia 2013; 56(4): 746-757.
83. Ioannou GN, Boyko EJ, Lee SP: The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. The American journal of gastroenterology 2006; 101(1): 76-82.
84. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P: Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998; 27(5): 1213-1219.
85. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. In: Seminars in liver disease: 2001; 2001: 15-22.
86. Ruhl CE, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. GASTROENTEROLOGY-BALTIMORE THEN PHILADELPHIA-2003; 124(1): 71-79.
87. Park SH, Heo NY, Park JH, Kim TO, Yang SY, Moon YS, Kim CH, Suk KT, Kim DJ, Lee HY: Obesity, insulin resistance, and the risk of an elevated alanine aminotransferase activity in the Korean adolescent population. Journal of Pediatric Endocrinology and Metabolism 2012; 25(9-10): 945-949.
88. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-419.
89. Bardella MT, Vecchi M, Conte D, Del Ninno E, Fraquelli M, Pacchetti S, Minola E, Landoni M, Cesana BM, De Franchis R: Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29(3): 654-657.
90. Abdo A, Meddings J, Swain M: Liver abnormalities in celiac disease. Clinical Gastroenterology and Hepatology 2004; 2(2): 107-112.
91. Hagander B, Berg N, Brandt L, Norden A, Sjölund K, Stenstam M: Hepatic injury in adult coeliac disease. The Lancet 1977; 310(8032): 270-272.
92. Bardella MT, Fraquelli M, Quatrini M, Molteni N, Bianchi P, Conte D: Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995; 22(3): 833-836.
93. Bonamico M, Pitzalis G, Culasso F, Vania A, Monti S, Benedetti C, Mariani P, Signoretti A: Hepatic damage in celiac disease in children]. Minerva pediatrica 1986; 38(21): 959.
94. Novacek G, Miehsler W, Wrba F, Ferenci P, Penner E, Vogelsang H: Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. European journal of gastroenterology & hepatology 1999; 11(3): 283-288.
95. Jacobsen M, Fausa O, Elgjo K, Schrumpf E: Hepatic lesions in adult coeliac disease. Scandinavian journal of gastroenterology 1990; 25(7): 656-662.
96. Janssen G, Kuipers H, Willems G, Does R, Janssen M, Geurten P: Plasma activity of muscle enzymes: quantification of skeletal muscle damage and relationship with metabolic variables. International journal of sports medicine 1989; 10(S 3): S160-S168.
97. Powell LW, George DK, McDonnell SM, Kowdley KV: Diagnosis of hemochromatosis. Annals of Internal Medicine 1998; 129(11_Part_2): 925-931.
98. Grossi E, Colombo R, Cavuto S, Franzini C: Age and gender relationships of serum alanine aminotransferase values in healthy subjects. The American journal of gastroenterology 2006; 101(7): 1675-1676.
99. Schooling CM, Kelvin EA, Jones HE: Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Annals of epidemiology 2012; 22(11): 789-798.
100. Elinav E, Ackerman Z, Maaravi Y, Ben-Dov IZ, Ein-Mor E, Stessman J: Low Alanine Aminotransferase Activity in Older People Is Associated with Greater Long-Term Mortality. Journal of the American Geriatrics Society 2006; 54(11): 1719-1724.
101. Liu Z, Ning H, Que S, Wang L, Qin X, Peng T: Complex Association between Alanine Aminotransferase Activity and Mortality in General Population: A Systematic Review and Meta-Analysis of Prospective Studies. PloS one 2014; 9(3e): 91410.
102. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Werch J: Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. New England Journal of Medicine 1981; 304(17): 989-994.
103. Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE: Donor transaminase and recipient hepatitis: impact on blood transfusion services. Jama 1981; 246(6): 630-634.
104. KAHN RA, JOHNSON G, AACH RD, HINES A, ELLIS FR, MILLER WV: The distribution of serum alanine aminotransferase levels in a blood donor population. American journal of epidemiology 1982; 115(6): 929-940.
105. Siest G, Schiele F, Galteau M-M, Panek E, Steinmetz J, Fagnani F, Gueguen R: Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clinical chemistry 1975; 21(8): 1077-1087.
106. Mathiesen U, Franzen L, Frydén A, Foberg U, Bodemar G: The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scandinavian journal of gastroenterology 1999; 34(1): 85-91.
107. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine 2002; 137(1): 1-10.
108. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ: Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010; 51(5): 1577-1583.
109. Kariv R, Leshno M, Beth-Or A, Strul H, Blendis L, Kokia E, Noff D, Zelber-Sagie S, Sheinberg B, Oren R: Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver International 2006; 26(4): 445-450.
110. Van der Poorten D, Kenny DT, Butler T, George J: Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology 2007; 46(6): 1750-1758.
111. Jamali R, Pourshams A, Amini S, Deyhim M-R, Rezvan H, Malekzadeh R: The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med 2008; 11(6): 602-607.
112. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Sateren WB, Scott PT, Michael NL, Robb ML, Birx DL, de Souza MS: Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PloS one 2008; 3(10e): 3327.
113. Kang HS, Um SH, Seo YS, An H, Lee KG, Hyun JJ, Kim ES, Park SC, Keum B, Kim JH: Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population. Journal of gastroenterology and hepatology 2011; 26(2): 292-299.
114. Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, Sirlin CB: SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138(4): 1357-1364. e1352.
115. Völzke H, Alte D, Ittermann T, Schmidt CO, Rettig R, Mayerle J, Lowenfels AB, Lerch MM, Nauck M: Subjects with sonographical hepatic steatosis should be excluded from studies to establish upper reference levels of serum transaminases. Liver International 2011; 31(7): 985-993.
116. Park SH, Park HY, Kang JW, Park J, Shin KJ: Aminotransferase upper reference limits and the prevalence of elevated aminotransferases in the Korean adolescent population. Journal of pediatric gastroenterology and nutrition 2012; 55(6): 668-672.
117. Wu WC, Wu CY, Wang YJ, Hung HH, Yang HI, Kao WY, Su CW, Wu JC, Chan WL, Lin HC: Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects. Alimentary pharmacology & therapeutics 2012, 36(6): 560-568.
118. Zheng M-H, Shi K-Q, Fan Y-C, Liu W-Y, Lin X-F, Li L-F, Chen Y-P: Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PloS one 2012; 7(9): e43736.
119. Al-hamoudi W, Ali S, Hegab B, Elsiesy H, Hashim A, Al-Sofayan M, Khalaf H, Al-Bahili H, Al-Masri N, Al-Sebayel M: Revising the Upper Limit of Normal for Levels of Serum Alanine Aminotransferase in a Middle Eastern Population with Normal Liver Histology. Digestive diseases and sciences 2013; 58(8): 2369-2375.
120. Kabir A, Pourshams A, Khoshnia M, Malekzadeh F: Normal Limit for Serum Alanine Aminotransferase Level and Distribution of Metabolic Factors in Old Population of Kalaleh, Iran. Hepatitis monthly 2013; 13(10).
121. Park SH, Heo NY, Kim CH, Suk KT, Kim DJ, Lee HY: Upper Reference Limits for Aminotransferase Activities and the Prevalence of Elevated Aminotransferase Activities in a Korean Population. Journal of Clinical Gastroenterology 2013; 47(1): 76-82.
122. Sohn W, Jun DW, Kwak MJ, Park Q, Lee KN, Lee HL, Lee OY, Yoon BC, Choi HS: Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. Journal of gastroenterology and hepatology 2013; 28(3): 522-529.
123. Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T: The upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatology Research 2013.
124. Kaplan MM: Alanine aminotransferase levels: what's normal? Annals of internal medicine 2002; 137(1): 49-51.
125. Bellentani S, Bedogni G, Tiribelli C: Liver and heart: A new link? Journal of hepatology 2008; 49(2): 300-302.
126. Yilmaz Y: Liver function tests: Association with cardiovascular outcomes. World journal of hepatology 2010; 2(4): 143.
127. Lioudaki E, Ganotakis E, Mikhailidis D: Liver enzymes: potential cardiovascular risk markers? Current pharmaceutical design 2011; 17(33): 3632-3643.
128. Goessling W, Massaro JM, Vasan RS, D'Agostino Sr RB, Ellison RC, Fox CS: Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135(6): 1935.
129. Monami M, Balzi D, Lamanna C, Melani C, Cocca C, Lotti E, Fedeli A, Masotti G, Marchionni N, Mannucci E: Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes/metabolism research and reviews 2007; 23(8): 625-630.
130. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M: Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191(2): 391-396.
131. Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, Buiatti E, Rotella CM, Mannucci E: Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008; 57(3): 387-392.
132. Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J: Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. The American journal of gastroenterology 2009; 104(7): 1715-1722.
133. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor D: Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake analysis of the British women's heart and health study and meta-analysis. Arteriosclerosis, thrombosis, and vascular biology 2007; 27(12): 2729-2735.
134. Emdin M, Passino C, Michelassi C, Donato L, Pompella A, Paolicchi A: Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. International journal of cardiology 2009; 136(1): 80-85.
135. Wang C-C, Kao J-H: Alanine Aminotransferase, Metabolic Syndrome, and Cardiovascular Disease: A Missing Link&quest. The American journal of gastroenterology 2010; 105(1): 224-224.
136. Adibi P, Sadeghi M, Mahsa M, Rozati G, Mohseni M: Prediction of coronary atherosclerotic disease with liver transaminase level. Liver International 2007; 27(7): 895-900.
137. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37(6): 1286-1292.
138. Kyrlagkitsis I, Portmann B, Smith H, O'Grady J, Cramp ME: Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. The American journal of gastroenterology 2003; 98(7): 1588-1593.
139. Siddiqui MS, Sterling RK, Luketic VA, Puri P, Stravitz RT, Bouneva I, Boyett S, Fuchs M, Sargeant C, Warnick GR: Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis. Gastroenterology 2013; 145(6): 1271-1279. e1273.
140. Park HK, Hwang JS, Moon JS, Lee JA, Kim DH, Lim JS: Healthy Range of Serum Alanine Aminotransferase and Its Predictive Power for Cardiovascular Risk in Children and Adolescents. Journal of pediatric gastroenterology and nutrition 2013; 56(6): 686-691.
141. Ozer JS, Chetty R, Kenna G, Palandra J, Zhang Y, Lanevschi A, Koppiker N, Souberbielle BE, Ramaiah SK: Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regulatory Toxicology and Pharmacology 2010; 56(3): 237-246.